{"editorial":{"content_id":"d62f47e0-16c5-4a40-8acb-d72e0f89a617","slug":"anvisa-glifit-glicofit-20261027-338a6f","content_type":"news","title":"巴西Anvisa叫停Glifit与Glicofit滴剂补充剂违规广告","summary":"巴西国家卫生监督局于10月27日决定暂停Vita Nutriom公司生产的Glifit和Glicofit两款滴剂膳食补充剂在互联网上的违规广告。","body":"巴西国家卫生监督局（Anvisa）于10月27日（周二）决定暂停Glifit和Glicofit两款滴剂膳食补充剂的广告。这两款产品由Vita Nutriom Saúde & Bem Estar Ltda公司生产（CNPJ税号：58.476.038/0001-15）。\n\nAnvisa指出，这些产品在多个网站发布的广告含有未经批准且具有误导性的治疗性、功能性和健康声明。被点名的违规宣称包括“真正的血糖调节器”“快速控制血糖水平”“改善胰岛素敏感性”“保持胰腺清洁和功能正常”“消除血糖峰值”等。\n\n相关决定以第4.224/2026号决议形式刊登于联邦官方公报（DOU）。Anvisa强调，发布虚假广告构成卫生违法行为，并触犯《消费者保护法典》规定的犯罪。\n\n巴西卫生法规禁止膳食补充剂作出减肥、增强专注力、提高免疫力、改善性功能、缓解经前紧张或更年期症状、治疗阿尔茨海默病和帕金森病等退行性疾病、自闭症谱系障碍、癌症、纤维肌痛、流感等宣称。","why_it_matters":null,"cbi_observation":null,"direction_tag":"巴西","primary_category":"科技平台","secondary_topics":["合规","法律","政策","br-health"],"content_level":"编辑整理","event_type":"政策法规","audience_tags":[],"event_location":null,"verification_status":"source_verified","published_at":"2026-10-27T23:01:10.573Z","display_date":"2026-10-27","source_published_at":null,"source_url":"https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2026/anvisa-suspende-propaganda-irregular-de-suplementos-alimentares","source_name":"Anvisa","source_language":"pt","author_name":"编辑部","risk_level":"low","risk_flags":["compliance_risk","legal_risk"],"opportunity_flags":[],"trend_signals":["policy_tightening"]},"intelligence":{"intel_id":"57979425-ceb1-4040-9944-131d84373f45","version":1,"event_type":"监管表态","event_date":"2026-10-27","main_entities":[{"name":"巴西国家卫生监督局（Anvisa）","role":"作出暂停违规广告决定的卫生监管机构","type":"regulator","country":"巴西","normalized_name":null},{"name":"Vita Nutriom Saúde & Bem Estar Ltda","role":"涉事膳食补充剂生产商，CNPJ税号58.476.038/0001-15","type":"company","country":"巴西","normalized_name":null},{"name":"Glifit","role":"被暂停广告的滴剂膳食补充剂","type":"product","country":"巴西","normalized_name":null},{"name":"Glicofit","role":"被暂停广告的滴剂膳食补充剂","type":"product","country":"巴西","normalized_name":null},{"name":"第4.224/2026号决议","role":"刊登于联邦官方公报的暂停广告决定","type":"policy","country":"巴西","normalized_name":null}],"main_action":"Anvisa暂停Vita Nutriom两款滴剂补充剂在互联网上的违规治疗性宣称广告","key_numbers":[{"unit":"款","label":"涉事产品数量","value":"2"},{"unit":"号","label":"决议编号","value":"4.224/2026"},{"unit":"税号","label":"公司CNPJ税号","value":"58.476.038/0001-15"}],"facts":[{"verified":true,"statement":"Anvisa于10月27日决定暂停Glifit和Glicofit两款滴剂膳食补充剂的广告。","source_excerpt":null},{"verified":true,"statement":"涉事产品由Vita Nutriom Saúde & Bem Estar Ltda生产，CNPJ税号为58.476.038/0001-15。","source_excerpt":null},{"verified":true,"statement":"Anvisa指出相关广告含有未经批准且具有误导性的治疗性、功能性和健康声明。","source_excerpt":null},{"verified":true,"statement":"被点名的违规宣称包括“真正的血糖调节器”“快速控制血糖水平”“改善胰岛素敏感性”“保持胰腺清洁和功能正常”“消除血糖峰值”。","source_excerpt":null},{"verified":true,"statement":"相关决定以第4.224/2026号决议形式刊登于联邦官方公报（DOU）。","source_excerpt":null},{"verified":true,"statement":"巴西卫生法规禁止膳食补充剂作出减肥、增强专注力、提高免疫力、改善性功能、缓解经前紧张或更年期症状、治疗退行性疾病、自闭症谱系障碍、癌症、纤维肌痛、流感等宣称。","source_excerpt":null}],"assessments":[{"statement":"该事件属于广告合规执法，而非产品注册或销售禁令，涉事企业主要面临宣传整改压力。","confidence":"medium","basis_fact_index":null},{"statement":"血糖调节类宣称是Anvisa对膳食补充剂广告的重点监控领域，同类产品在巴西市场存在较高合规风险。","confidence":"high","basis_fact_index":null},{"statement":"发布虚假广告在巴西可能同时触发卫生行政违法与消费者保护法项下的法律责任。","confidence":"high","basis_fact_index":null}],"actions":[{"target":"both","priority":"high","description":"核查涉事企业及关联品牌在巴西其他在售产品的宣称合规性。"},{"target":"system","priority":"normal","description":"将Anvisa膳食补充剂禁用宣称清单纳入对巴西市场健康类产品的合规筛查模板。"},{"target":"user","priority":"normal","description":"持续跟踪第4.224/2026号决议全文及后续处罚进展。"}],"affected_audience":["巴西膳食补充剂消费者","在巴销售膳食补充剂的企业","跨境电商健康品类卖家","血糖相关健康产品营销方"],"risk_flags":["compliance_risk","legal_risk"],"opportunity_flags":[],"trend_signals":["policy_tightening"],"follow_up_needed":true,"follow_up_questions":["第4.224/2026号决议是否包含罚款金额或整改期限？","Anvisa是否对Vita Nutriom其他产品或销售渠道采取进一步措施？","涉事产品是否已在电商平台下架？"],"related_topics":["Anvisa","膳食补充剂广告监管","血糖调节宣称","Vita Nutriom","联邦官方公报","消费者保护法典"],"verification_status":"unverified","confidence_score":0.7,"generated_at":"2026-10-27T23:01:20.448Z"},"meta":{"canonical_url":"https://chinabrazilinsight.com/news/anvisa-glifit-glicofit-20261027-338a6f","api_url":"https://chinabrazilinsight.com/api/public/content/anvisa-glifit-glicofit-20261027-338a6f","markdown_url":"https://chinabrazilinsight.com/api/public/content/anvisa-glifit-glicofit-20261027-338a6f?view=markdown","json_url":"https://chinabrazilinsight.com/api/public/content/anvisa-glifit-glicofit-20261027-338a6f?view=json","last_updated":"2026-10-27T23:01:20.774Z","platform":"China Brazil Insight","platform_url":"https://chinabrazilinsight.com"}}